Zealand Pharma Faces Setbacks, Analysts Reassess Obesity Drug Strategy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Drug Efficacy Issues: Zealand Pharma's obesity drug survodutide faced significant setbacks with a 19% patient dropout rate, prompting analysts to slash peak sales forecasts by nearly 80%, which will severely impact the company's market performance and investor confidence.
- Optimistic Outlook for New Drug: Despite disappointing tolerability data for survodutide, analysts remain positive about the amylin-based drug petrelintide, believing it has the potential for modest weight loss and excellent tolerability, positioning it as a future growth driver.
- Intensifying Market Competition: At the American Diabetes Association meeting, the demand for amylin drugs was widely recognized, and Zealand's petrelintide faces competition from major players like Eli Lilly, necessitating a clear differentiation to attract patients in a crowded market.
- Crucial Future Trials: Petrelintide is set to initiate late-stage trials in the second half of the year, and analysts believe its success will directly influence Zealand's market position, particularly in the treatment of obesity and fatty liver disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 43.520
Low
42.00
Averages
54.67
High
70.00
Current: 43.520
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zealand Pharma Shares Plunge 23% Amid Survodutide Concerns
- Drug Efficacy Concerns: Zealand Pharma's weight loss drug, survodutide, has shown a 19% patient dropout rate due to side effects in clinical trials, prompting analysts to slash peak sales forecasts by nearly 80%, posing a significant challenge to the company's obesity treatment strategy.
- Stock Volatility: The company's stock plummeted 23% earlier this month and dropped 36% in March due to lower-than-expected efficacy of another drug, petrelintide, marking the two worst performances since its IPO in 2010, with a year-to-date decline of 38%.
- Shift in Market Focus: Despite the bleak outlook for survodutide, investors are shifting their attention to petrelintide, with analysts believing it still holds potential in the weight loss market, especially with upcoming late-stage trials.
- Increased Competitive Pressure: At the American Diabetes Association meeting, amylin drugs like petrelintide were highlighted as key future players, and despite competition from major firms like Eli Lilly, Zealand Pharma still has opportunities to carve out a niche in the obesity market.
See More
Zealand Pharma Faces Setbacks, Analysts Reassess Obesity Drug Strategy
- Drug Efficacy Issues: Zealand Pharma's obesity drug survodutide faced significant setbacks with a 19% patient dropout rate, prompting analysts to slash peak sales forecasts by nearly 80%, which will severely impact the company's market performance and investor confidence.
- Optimistic Outlook for New Drug: Despite disappointing tolerability data for survodutide, analysts remain positive about the amylin-based drug petrelintide, believing it has the potential for modest weight loss and excellent tolerability, positioning it as a future growth driver.
- Intensifying Market Competition: At the American Diabetes Association meeting, the demand for amylin drugs was widely recognized, and Zealand's petrelintide faces competition from major players like Eli Lilly, necessitating a clear differentiation to attract patients in a crowded market.
- Crucial Future Trials: Petrelintide is set to initiate late-stage trials in the second half of the year, and analysts believe its success will directly influence Zealand's market position, particularly in the treatment of obesity and fatty liver disease.
See More
Hims & Hers Partners with Novo Nordisk, Boosting Stock Momentum
- Growth Through Partnership: Novo Nordisk announced on March 9 that it will sell its blockbuster drugs Wegovy and Ozempic through Hims & Hers, with Barclays noting improved customer momentum, indicating a positive impact from the collaboration.
- Price Target Increase: Barclays raised its price target for Hims & Hers from $29 to $39, implying a 21% upside from the last closing price, reflecting increased confidence in the company's future growth trajectory.
- Revenue Acceleration Expectations: Revenue and EBITDA for Hims & Hers are expected to significantly accelerate in the second half of 2026 due to strong demand for weight-loss products and contributions from other business lines, further solidifying its market position.
- Market Sentiment Rebound: Retail sentiment for Hims & Hers improved from 'bullish' to 'extremely bullish', with message activity rising over 120% in the past week, indicating investor optimism regarding the company's outlook.
See More
Recap of CNBC Investing Club Monthly Meeting
- Portfolio Analysis: During the June Monthly Meeting, Jim Cramer and Jeff Marks provided an in-depth analysis of 35 portfolio stocks, highlighting their preference for Intel due to its significant upside potential in data center CPU growth, particularly in the context of competition with TSMC.
- Tech Giants Restructuring: Cramer noted a reordering of the 'Magnificent Seven,' with newcomers like SpaceX and the yet-to-go-public Anthropic and OpenAI emerging as formidable competitors, indicating intensified market competition, especially in the AI sector.
- Strengths of Alphabet and Apple: Alphabet is positioned advantageously in the AI era with its YouTube and Waymo businesses, while Apple leverages its ecosystem of over 2.5 billion iPhone users to strengthen its AI partnership with Alphabet, showcasing both companies' robust market positions.
- Market Dynamics and Investment Strategy: Despite challenges faced by Meta and Microsoft, Cramer advises maintaining investments in Amazon and Nvidia, believing that the latter's GPU demand will continue to grow, and that Amazon's cloud business remains highly profitable.
See More
Novo Nordisk to File for Wegovy Approval in China Soon
- Market Expansion Plans: Novo Nordisk's CEO Mike Doustdar announced that the company will submit its Wegovy weight-loss pill for regulatory approval in China within a few months, indicating its intent to expand in the world's second-largest market and compete with Eli Lilly's orforglipron.
- Product Launch Context: Wegovy was launched in the U.S. earlier this year after receiving FDA approval in December, and Novo Nordisk aims to mitigate potential impacts on its GLP-1 franchise from the upcoming patent expiry of semaglutide, the active ingredient in its diabetes therapies, by introducing Wegovy in China.
- Competitive Advantage Analysis: Doustdar noted that one barrier to entry for Wegovy will be the scaling of production capabilities, suggesting that not many competitors will have the necessary capacity, which could provide Novo Nordisk with a strategic edge in the Chinese market.
- Industry Dynamics Observation: Eli Lilly submitted its marketing application for its oral GLP-1 therapy orforglipron to Chinese regulators at the end of last year, highlighting the intensifying competition in this sector, and Novo Nordisk's timely application will help position it effectively in the market.
See More
FDA Issues Warning Letters to Telehealth Firms Over Misleading GLP-1 Claims
- Warning Letter Count: The FDA has issued 25 warning letters to telehealth firms for allegedly making false claims about low-cost compounded GLP-1 drugs, indicating the regulator's stringent oversight of the market.
- Product Safety Concerns: The FDA emphasized that these compounded drugs have not been proven safe or effective compared to FDA-approved GLP-1 medications from Novo Nordisk (NVO) and Eli Lilly (LLY), posing potential health risks to consumers and highlighting the importance of consumer protection.
- Market Reaction: Compounded GLP-1 drugs surged in popularity due to shortages of branded medications, with the FDA sending over 100 warning letters to telehealth firms, including Hims & Hers (HIMS), demonstrating a zero-tolerance approach to misleading marketing.
- Industry Impact: Following a deal with Novo Nordisk, HIMS ceased marketing its compounded GLP-1 drugs in favor of branded options, reflecting a growing emphasis on compliance and consumer trust, which may influence future market strategies.
See More
Zealand Pharma Shares Plunge 23% Amid Survodutide Concerns
- Drug Efficacy Concerns: Zealand Pharma's weight loss drug, survodutide, has shown a 19% patient dropout rate due to side effects in clinical trials, prompting analysts to slash peak sales forecasts by nearly 80%, posing a significant challenge to the company's obesity treatment strategy.
- Stock Volatility: The company's stock plummeted 23% earlier this month and dropped 36% in March due to lower-than-expected efficacy of another drug, petrelintide, marking the two worst performances since its IPO in 2010, with a year-to-date decline of 38%.
- Shift in Market Focus: Despite the bleak outlook for survodutide, investors are shifting their attention to petrelintide, with analysts believing it still holds potential in the weight loss market, especially with upcoming late-stage trials.
- Increased Competitive Pressure: At the American Diabetes Association meeting, amylin drugs like petrelintide were highlighted as key future players, and despite competition from major firms like Eli Lilly, Zealand Pharma still has opportunities to carve out a niche in the obesity market.
See More
Zealand Pharma Faces Setbacks, Analysts Reassess Obesity Drug Strategy
- Drug Efficacy Issues: Zealand Pharma's obesity drug survodutide faced significant setbacks with a 19% patient dropout rate, prompting analysts to slash peak sales forecasts by nearly 80%, which will severely impact the company's market performance and investor confidence.
- Optimistic Outlook for New Drug: Despite disappointing tolerability data for survodutide, analysts remain positive about the amylin-based drug petrelintide, believing it has the potential for modest weight loss and excellent tolerability, positioning it as a future growth driver.
- Intensifying Market Competition: At the American Diabetes Association meeting, the demand for amylin drugs was widely recognized, and Zealand's petrelintide faces competition from major players like Eli Lilly, necessitating a clear differentiation to attract patients in a crowded market.
- Crucial Future Trials: Petrelintide is set to initiate late-stage trials in the second half of the year, and analysts believe its success will directly influence Zealand's market position, particularly in the treatment of obesity and fatty liver disease.
See More
Hims & Hers Partners with Novo Nordisk, Boosting Stock Momentum
- Growth Through Partnership: Novo Nordisk announced on March 9 that it will sell its blockbuster drugs Wegovy and Ozempic through Hims & Hers, with Barclays noting improved customer momentum, indicating a positive impact from the collaboration.
- Price Target Increase: Barclays raised its price target for Hims & Hers from $29 to $39, implying a 21% upside from the last closing price, reflecting increased confidence in the company's future growth trajectory.
- Revenue Acceleration Expectations: Revenue and EBITDA for Hims & Hers are expected to significantly accelerate in the second half of 2026 due to strong demand for weight-loss products and contributions from other business lines, further solidifying its market position.
- Market Sentiment Rebound: Retail sentiment for Hims & Hers improved from 'bullish' to 'extremely bullish', with message activity rising over 120% in the past week, indicating investor optimism regarding the company's outlook.
See More
Recap of CNBC Investing Club Monthly Meeting
- Portfolio Analysis: During the June Monthly Meeting, Jim Cramer and Jeff Marks provided an in-depth analysis of 35 portfolio stocks, highlighting their preference for Intel due to its significant upside potential in data center CPU growth, particularly in the context of competition with TSMC.
- Tech Giants Restructuring: Cramer noted a reordering of the 'Magnificent Seven,' with newcomers like SpaceX and the yet-to-go-public Anthropic and OpenAI emerging as formidable competitors, indicating intensified market competition, especially in the AI sector.
- Strengths of Alphabet and Apple: Alphabet is positioned advantageously in the AI era with its YouTube and Waymo businesses, while Apple leverages its ecosystem of over 2.5 billion iPhone users to strengthen its AI partnership with Alphabet, showcasing both companies' robust market positions.
- Market Dynamics and Investment Strategy: Despite challenges faced by Meta and Microsoft, Cramer advises maintaining investments in Amazon and Nvidia, believing that the latter's GPU demand will continue to grow, and that Amazon's cloud business remains highly profitable.
See More
Novo Nordisk to File for Wegovy Approval in China Soon
- Market Expansion Plans: Novo Nordisk's CEO Mike Doustdar announced that the company will submit its Wegovy weight-loss pill for regulatory approval in China within a few months, indicating its intent to expand in the world's second-largest market and compete with Eli Lilly's orforglipron.
- Product Launch Context: Wegovy was launched in the U.S. earlier this year after receiving FDA approval in December, and Novo Nordisk aims to mitigate potential impacts on its GLP-1 franchise from the upcoming patent expiry of semaglutide, the active ingredient in its diabetes therapies, by introducing Wegovy in China.
- Competitive Advantage Analysis: Doustdar noted that one barrier to entry for Wegovy will be the scaling of production capabilities, suggesting that not many competitors will have the necessary capacity, which could provide Novo Nordisk with a strategic edge in the Chinese market.
- Industry Dynamics Observation: Eli Lilly submitted its marketing application for its oral GLP-1 therapy orforglipron to Chinese regulators at the end of last year, highlighting the intensifying competition in this sector, and Novo Nordisk's timely application will help position it effectively in the market.
See More
FDA Issues Warning Letters to Telehealth Firms Over Misleading GLP-1 Claims
- Warning Letter Count: The FDA has issued 25 warning letters to telehealth firms for allegedly making false claims about low-cost compounded GLP-1 drugs, indicating the regulator's stringent oversight of the market.
- Product Safety Concerns: The FDA emphasized that these compounded drugs have not been proven safe or effective compared to FDA-approved GLP-1 medications from Novo Nordisk (NVO) and Eli Lilly (LLY), posing potential health risks to consumers and highlighting the importance of consumer protection.
- Market Reaction: Compounded GLP-1 drugs surged in popularity due to shortages of branded medications, with the FDA sending over 100 warning letters to telehealth firms, including Hims & Hers (HIMS), demonstrating a zero-tolerance approach to misleading marketing.
- Industry Impact: Following a deal with Novo Nordisk, HIMS ceased marketing its compounded GLP-1 drugs in favor of branded options, reflecting a growing emphasis on compliance and consumer trust, which may influence future market strategies.
See More
